36 results on '"Pavone, Piero"'
Search Results
2. Simple febrile seizures: new cut off for the duration of the crises.
- Author
-
Falsaperla R, Marino S, Vitaliti G, Bonadies A, Marino SD, Pavone P, Romano C, Savoia F, Calì C, Ruggieri M, Lubrano R, and Tipo V
- Subjects
- Child, Humans, Infant, Retrospective Studies, Fever, Hospitals, University, Seizures, Febrile diagnosis, Seizures, Febrile epidemiology, Epilepsy epidemiology
- Abstract
Background: Our study aimed to identify a new cut-off for febrile seizure (FS) with a good prognosis, thereby replacing the 15 min described in the standard definition of simple febrile seizure (SFS)., Methods: Our study was a retrospective observational study (from January 2018 to December 2018) on children admitted to the Pediatric emergency room of the Santobono-Pausilipon Hospital, Naples, Italy, Pediatric Unit of Latina, Rome, Italy, and Policlinico-Vittorio-Emanuele University Hospital, Catania, Italy, for fever, which developed SFS during the hospitalization. All included patients had their seizures classified as SFS according to the international criteria for epilepsy. We assumed a duration cut-off, and we analyzed the EEG results, neurological follow-up at 12 months, and the recurrence of the febrile seizures the following year. Then, with another calculation, we identify an optimal cut-off of 6 min. Finally, we divided the population into two groups: children with seizures having a duration greater than or less than 6 min., Results: We found that the population with FS with a duration greater than 6 min presented EEG alteration at follow-up visits, neurological disorders, and a recurrence of FS during the following year., Conclusions: We suggest to introduce a new cut-off for the duration of FS that better represents the benign nature of a simple febrile event., (© 2023. The Author(s) under exclusive licence to Belgian Neurological Society.)
- Published
- 2023
- Full Text
- View/download PDF
3. Clinical and electroencephalographic features of epilepsy in patients with triple X syndrome: A case series.
- Author
-
Dell'Isola GB, Mencaroni E, Prontera P, Cara GD, Ferraro L, Bonanni P, Carotenuto M, Iapadre G, Matricardi S, Operto F, Orsini A, Parisi P, Pavone P, Salpietro V, Savasta S, Striano P, and Verrotti A
- Subjects
- Female, Humans, Levetiracetam therapeutic use, Valproic Acid therapeutic use, Retrospective Studies, Electroencephalography, Anticonvulsants therapeutic use, Epilepsy complications, Epilepsy diagnosis, Epilepsy drug therapy
- Abstract
Purpose: Triple X syndrome, is an often undiagnosed chromosomal abnormality with an incidence of 1/1000 females. Main associated disorders are urogenital malformations, premature ovarian failure or primary amenorrhea, gastrointestinal problems, psychiatric disorders and epilepsy. To date, triple X is not related to a specific epileptic syndrome. Therefore, the purpose of this clinical series is to analyze seizure semiology, electroencephalogram features and the long-term outcome of 13 patients with epilepsy and triple X syndrome., Methods: We retrospectively evaluated the long-term seizure outcome in patients with triple X syndrome who had been referred to 11 Epilepsy Centers in Italy. A close electroclinical follow-up was made for at least 2 years and outcomes were reported., Results: Our case series confirms that epilepsy is not an occasional finding but part of the phenotypic spectrum of this syndrome. The seizure semiology shows an higher prevalence of focal seizures in 62% of patients. EEG findings of focal epileptic activity were reported in 85% of patients. Anti-seizure medications were successful in all our patients whom in most cases were responsive to monotherapy., Conclusion: According to our case series most successful drugs were VPA and LEV. Long term prognosis of epilepsy in our case series was good. Our experience suggests that all triple X patients achieve good seizure control and in 69% of cases normalization of the EEG., Competing Interests: Declaration of Competing Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
4. Ocular Motor Paroxysmal Events in Neonates and Infants: A Review of the Literature.
- Author
-
Falsaperla R, Saporito MAN, Pisani F, Mailo J, Pavone P, Ruggieri M, Suppiej A, and Corsello G
- Subjects
- Diagnosis, Differential, Electroencephalography, Epilepsy complications, Humans, Infant, Infant, Newborn, Epilepsy diagnosis, Ocular Motility Disorders diagnosis, Ocular Motility Disorders etiology
- Abstract
Background: Ocular paroxysmal events can accompany a variety of neurological disorders. Particularly in infants, ocular paroxysmal events often represent a diagnostic challenge. Distinguishing between epileptic and nonepileptic events or between physiological and pathologic paroxysmal events can be challenging at this age because the clinical evaluation and physical examination are often limited. Continuous polygraphic video-electroencephalography (EEG) monitoring can be helpful in these situations., Methods: We review ocular paroxysmal events in newborns and infants. The aim is to improve clinical recognition of ocular paroxysmal events and provide a guide to further management. Using the PubMed database, we identified studies focused on all ocular motor paroxysmal events in neonates and infants., Results: Fifty-eight articles were selected on the topic. We summarized and divided these studies into those describing nonepileptic and epileptic ocular paroxysmal events., Conclusions: The diagnosis of ocular paroxysmal events can be difficult, but their recognition is important because of the variety of underlying etiologies. The distinction between epileptic versus nonepileptic ocular paroxysmal events often often requires polygraphic video-EEG to identify the epileptic events. For nonepileptic events, further testing can characterize pathologic ocular movements. To determine the etiology and prognosis of ocular paroxysmal events, a multimodal approach is required, including a thorough full history and clinical examination, polygraphic video-EEG monitoring, neuroimaging, and a careful follow-up plan., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
5. Ketogenic diet for infants with epilepsy: A literature review.
- Author
-
Falsaperla R, D'Angelo G, Praticò AD, Mauceri L, Barbagallo M, Pavone P, Catanzaro S, Gitto E, Corsello G, and Ruggieri M
- Subjects
- Diet, Ketogenic adverse effects, Disease Management, Female, Glucose Transporter Type 1, Humans, Infant, Infant, Newborn, Male, Seizures etiology, Treatment Outcome, Diet, Ketogenic methods, Drug Resistant Epilepsy diet therapy, Epilepsy diet therapy
- Abstract
The ketogenic diet (KD) is an established, nonpharmacological treatment for drug-resistant epilepsy (DRE). Actually, KD and its variants have been shown to be elective and resolute for patients with glucose transporter type 1 (GLUT1) deficiency. The aim of this review was to study the use of KD and its variants in infancy, including the neonatal age, and demonstrate the safety and efficacy of this treatment in patients with the age of 0-23 months affected by DRE already subjected to pharmacological approach attempts. A literature search was conducted using PubMed as the medical database source. We used the age limit of 0-23 months, and we considered only articles published between the years 2015 and 2018, in light of increasing interest worldwide in the use of KD and its variants to manage DRE. We included 52 publications: 1 Cochrane study, 22 retrospective studies, 9 prospective studies, 4 randomized controlled trials (RCTs), 12 clinical cases, and 4 clinical reviews. Literature data showed that KD and its variants are safe and useful in patients with the age of 0-23 months with DRE. Classical KD is of first choice in the treatment of GLUT1 deficiency. Earlier introduction of KD in GLUT1 promises a better outcome and a decrease in seizure frequency in these patients., Competing Interests: Declaration of competing interest None., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
6. Celiac disease and headache in children: a narrative state of the art.
- Author
-
Sabino L, Marino S, Falsaperla R, Pisani F, Massimino C, and Pavone P
- Subjects
- Child, Diet, Gluten-Free, Glutens, Headache etiology, Humans, Celiac Disease complications, Celiac Disease diagnosis, Epilepsy
- Abstract
Celiac disease (CD) is one of the most important entity of the wide spectrum of gluten-related disorders (GRDs). It is well known that neurological manifestation can be present either at the onset of CD, or appear during the development of the pathology, and different can be the neurologic findings. Clinical features are very variable, ranging from typical manifestations of gastrointestinal involvement to neurologic symptom. The most frequent neurologic signs reported were headache, epileptic seizure, migraine, mental retardation, ataxia and attention deficit and hyperactive disorder. Headache either in form of migraine, or in non-specific form represents one of the main clinical presentation in CD. The aim of this work is to provide a narrative review of the pediatric literature focused on the cephalalgic features of children with CD evaluating the potential benefits of a gluten free diet (GFD). Papers were identified by searching for related literature in Medline (PubMed) and Embase using the words "Celiac Disease" and "Headache" or "Migraine" by specifying "children"/"paediatric age" for reports published since 1972 till 31th October 2018. According to our inclusion criteria, a total of 25 papers has been evaluated. Although it is still controversial if headache is prevalent in CD children a correct compliance to a GFD seems to improve the neurological symptoms even if the underlying pathogenic relationship between CD and neurologic system involvement is still not fully understood.
- Published
- 2020
- Full Text
- View/download PDF
7. 7q31.32 partial duplication: First report of a child with dysmorphism, autistic spectrum disorder, moderate intellectual disability and, epilepsy. Literature review.
- Author
-
Pavone P, Corsello G, Marino SD, Ruggieri M, and Falsaperla R
- Subjects
- Genetic Association Studies, Humans, Autism Spectrum Disorder genetics, Chromosomes, Human, Pair 7 genetics, Developmental Disabilities genetics, Epilepsy genetics, Intellectual Disability genetics
- Abstract
Introduction: Duplication of long arm of chromosome 7(q) is uncommon. It may occur as "pure", isolated anomaly or in association with other mutations involving the same or other chromosomes. "Pure" chromosome 7q duplication has recently been classified by segment involved: the interstitial, proximal, or distal segment of the arm. Attempts to correlate genotype with phenotype in each group has yielded questionable results even though intellective disability and minor dysmorphic features of variable types are typically seen., Material and Methods: In a young boy showing minor facial dysmorphism, language delay, autistic spectrum disorder, epileptic seizures, behavioral disturbances and irritability an array-CGH analysis was carried out., Results: Array-CGH analysis found in the proband a de novo variant of partial duplication of 7q31.32 (122.254.792-122.376.908)., Discussion: A very few cases of partial 7q duplication have been reported thus far mainly presenting with clinical signs of dysmorphic features, large head, developmental delay, epileptic seizures and skeletal anomalies. To our knowledge, this is the first report of a case of a de novo variant of 7q31.32 duplication, showing dysmorphic anomalies and neurologic impairment including ASD and seizures. In the 7q31.32 region is located the gene CADPS2, which has been associated to autistic spectrum disorder and other neurologic disorders. In the child, a genotype-phenotype correlation may be hypothesized. Further similar reports may be useful to confirm this observation., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
8. Hypomelanosis of Ito: a round on the frequency and type of epileptic complications.
- Author
-
Pavone P, Praticò AD, Ruggieri M, and Falsaperla R
- Subjects
- Adult, Child, Electroencephalography, Female, Humans, Hypopigmentation pathology, Magnetic Resonance Imaging, Male, Epilepsy etiology, Hypopigmentation complications
- Abstract
There is an ample evidence that hypopigmentation of the skin along the Blaschko's lines is frequently associated with neurological disorders. Nowadays, the term "Hypomelanosis of Ito" (HI) is applied when, together with the cutaneous lesions, various and multisystem organs are involved. Among these, the most frequent are cerebral manifestations, such as cognitive delay and epileptic seizures. For this reason, hypomelanosis of Ito has been included in the group of neurocutaneous syndromes, neurologic manifestations being one of the most frequent. Epileptic seizures have been reported in patients with this disorder, but in a very few particular attention has been focused on the type and frequency of epilepsy and on the response to the treatment. Herein, we report on five patients with HI who showed episodes of epileptic seizures with onset in childhood, in absence of malformative anomalies except for the skin lesions. A survey on the frequency and types of epileptic seizures in HI children and in the literature is reported.
- Published
- 2015
- Full Text
- View/download PDF
9. Epilepsy and innate immune system: A possible immunogenic predisposition and related therapeutic implications.
- Author
-
Matin N, Tabatabaie O, Falsaperla R, Lubrano R, Pavone P, Mahmood F, Gullotta M, Serra A, Di Mauro P, Cocuzza S, and Vitaliti G
- Subjects
- Animals, Epilepsy therapy, Humans, Disease Susceptibility, Epilepsy immunology, Epilepsy pathology, Immunologic Factors therapeutic use, Inflammation, Neuroimmunomodulation
- Abstract
Recent experimental studies and pathological analyses of patient brain tissue samples with refractory epilepsy suggest that inflammatory processes and neuroinflammation plays a key-role in the etiopathology of epilepsy and convulsive disorders. These inflammatory processes lead to the secretion of pro-inflammatory cytokines responsible for blood-brain-barrier disruption and involvement of resident immune cells in the inflammation pathway, occurring within the Central Nervous System (CNS). These elements are produced through activation of Toll-Like Receptors (TLRs) by exogenous and endogenous ligands thereby increasing expression of cytokines and co-stimulatory molecules through the activation of TLRs 2, 3, 4, and 9 as reported in murine studies.It has been demonstrated that IL-1β intracellular signaling and cascade is able to alter the neuronal excitability without cell loss. The activation of the IL-1β/ IL-1β R axis is strictly linked to the secretion of the intracellular protein MyD88, which interacts with other cell surface receptors, such as TLR4 during pathogenic recognition. Furthermore, TLR-signaling pathways are able to recognize molecules released from damaged tissues, such as damage-associated molecular patterns/proteins (DAMPs). Among these molecules, High-mobility group box-1 (HMGB1) is a component of chromatin that is passively released from necrotic cells and actively released by cells that are subject to profound stress. Moreover, recent studies have described models of epilepsy induced by the administration of bicuculline and kainic acid that highlight the nature of HMGB1-TLR4 interactions, their intracellular signaling pathway as well as their role in ictiogenesis and epileptic recurrence.The aim of our review is to focus on different branches of innate immunity and their role in epilepsy, emphasizing the role of immune related molecules in epileptogenesis and highlighting the research implications for novel therapeutic strategies.
- Published
- 2015
- Full Text
- View/download PDF
10. Targeting inflammation as a therapeutic strategy for drug-resistant epilepsies: an update of new immune-modulating approaches.
- Author
-
Vitaliti G, Pavone P, Mahmood F, Nunnari G, and Falsaperla R
- Subjects
- Animals, Disease Models, Animal, Epilepsy immunology, Humans, Anti-Inflammatory Agents therapeutic use, Drug Resistance, Epilepsy drug therapy, Epilepsy pathology, Neurogenic Inflammation drug therapy, Neuroimmunomodulation
- Abstract
An increasing body of literature data suggests that inflammation, and in particular neuroinflammation, is involved in the pathophysiology of particular forms of epilepsy and convulsive disorders. Animal models have been used to identify inflammatory triggers in epileptogenesis and inflammation has recently been shown to enhance seizures. For example, pharmacological blockade of the IL-1beta/IL-1 receptor type 1 axis during epileptogenesis has been demonstrated to provide neuroprotection in temporal lobe epilepsy. Furthermore, experimental models have suggested that neural damage and the onset of spontaneous recurrent seizures are modulated via complex interactions between innate and adaptive immunity. However, it has also been suggested that inflammation can occur as a result of epilepsy, since animal models have also shown that seizure activity can induce neuroinflammation, and that recurrent seizures maintain chronic inflammation, thereby perpetuating seizures. On the basis of these observations, it has been suggested that immune-mediated therapeutic strategies may be beneficial for treating some drug resistant epilepsies with an underlying demonstrable inflammatory process. Although the potential mechanisms of immunotherapeutic strategies in drug-resistant seizures have been extensively discussed, evidence on the efficacy of such therapy is limited. However, recent research efforts have been directed toward utilizing the potential therapeutic benefits of anti-inflammatory agents in neurological disease and these are now considered prime candidates in the ongoing search for novel anti-epileptic drugs. The objective of our review is to highlight the immunological features of the pathogenesis of seizures and to analyze possible immunotherapeutic approaches for drug resistant epilepsies that can alter the immune-mediated pathogenesis.
- Published
- 2014
- Full Text
- View/download PDF
11. Electroclinical features and long-term outcome of cryptogenic epilepsy in children with Down syndrome.
- Author
-
Verrotti A, Cusmai R, Nicita F, Pizzolorusso A, Elia M, Zamponi N, Cesaroni E, Granata T, De Giorgi I, Giordano L, Grosso S, Pavone P, Franzoni E, Coppola G, Cerminara C, Curatolo P, Savasta S, Striano P, Parisi P, Romeo A, and Spalice A
- Subjects
- Adolescent, Anticonvulsants therapeutic use, Child, Child, Preschool, Electroencephalography, Epilepsy drug therapy, Female, Humans, Infant, Male, Retrospective Studies, Time Factors, Down Syndrome complications, Epilepsy complications, Epilepsy physiopathology
- Abstract
Objective: To describe the electroclinical features and the long-term outcomes of epilepsy in a large cohort of males and females with Down syndrome who developed epilepsy in childhood., Study Design: Subjects with Down syndrome and cryptogenic epilepsy with onset in childhood were identified retrospectively from the databases of 16 Italian epilepsy centers over a 40-year period. For each subject, age at onset of seizures, seizure semiology and frequency, electroencephalography characteristics, treatment with antiepileptic drugs, and long-term clinical and electroencephalography outcomes were analyzed., Results: A total of 104 subjects (64 males [61.5%], 40 females [38.5%]) were identified. Seizure onset occurred within 1 year of birth in 54 subjects (51.9%), between 1 and 12 years in 42 subjects (40.4%), and after 12 years in 8 subjects (7.7%). Males had a younger age of seizure onset than females. Of the 104 subjects, 51 (49.0%) had infantile spasms (IS), 35 (33.7%) had partial seizures (PS), and 18 (17.3%) had generalized seizures (GS). Febrile seizures were recorded in 5 (4.8%) subjects. Intractable seizures were observed in 23 (22.1%) subjects, including 5 (9.8%) with IS, 8 (44.4%) with PS, and 10 (31.3%) with GS., Conclusion: Cryptogenic epilepsy in Down syndrome may develop during the first year of life in the form of IS or, successively, as PS or GS. Electroclinical features of IS resemble those of idiopathic West syndrome, with a favorable response to treatment with adrenocorticotropic hormone seen. Patients experiencing PS and GS may be resistant to therapy with antiepileptic drugs., (Copyright © 2013 Mosby, Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
12. Lacosamide in pediatric and adult patients: comparison of efficacy and safety.
- Author
-
Verrotti A, Loiacono G, Pizzolorusso A, Parisi P, Bruni O, Luchetti A, Zamponi N, Cappanera S, Grosso S, Kluger G, Janello C, Franzoni E, Elia M, Spalice A, Coppola G, Striano P, Pavone P, Savasta S, Viri M, Romeo A, Aloisi P, Gobbi G, Ferretti A, Cusmai R, and Curatolo P
- Subjects
- Acetamides administration & dosage, Acetamides adverse effects, Adolescent, Adult, Anticonvulsants administration & dosage, Anticonvulsants adverse effects, Child, Child, Preschool, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Lacosamide, Male, Treatment Outcome, Acetamides therapeutic use, Anticonvulsants therapeutic use, Epilepsy drug therapy
- Abstract
Purpose: This multicenter, prospective study investigates the efficacy and safety of lacosamide adjunctive therapy in pediatric and adult patients with uncontrolled epilepsy., Method: This study was carried out between September 2010 and December 2011 at 16 Italian and 1 German neurologic centers. Lacosamide was added to the baseline therapy at a starting dose of 1 mg/kg/day in patients aged <16 years (group A) and 100 mg daily in subjects aged 16 and older (group B), and titrated to the target dose, ranging from 3 to 12 mg/kg/day or from 100 to 600 mg daily, respectively. After completing the titration period, patients entered a 12-month maintenance period and they were followed up at 3, 6 and 12 months. The primary assessment of efficacy was based on the change from baseline in seizure frequency per 28 days and was evaluated at 3, 6 and 12 months as follows: number and proportion of 100% responders, 50% responders, non-responders and worsening patients. Safety evaluation was also performed at 3, 6 and 12 months., Results: A total of 118 patients (59 group A, 59 group B) with uncontrolled generalized and focal epilepsy were enrolled. Patient mean±SD age was 15.9±6.80 years and the age range was 4-38 years. At 3-month evaluation, of 118 treated patients 56 subjects (47.4% group A; 47.4% group B; p=0.8537) experienced at least a 50% reduction in seizure frequency. At 6 and 12-month follow-up, the 50% responders were 57 (52.5% group A; 44.1% group B; p=0.4612) and 51 (47.4% group A; 39% group B; p=0.4573), respectively. Thirty-five subjects (30.5% group A; 28.8% group B; p=1) experienced side effects during the treatment period. The most common adverse events were dyspepsia for group A and dizziness for group B., Conclusion: Lacosamide may be a useful and safe pharmacological treatment option for both pediatric and adult patients with uncontrolled seizures., (Copyright © 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
13. Ohtahara syndrome with emphasis on recent genetic discovery.
- Author
-
Pavone P, Spalice A, Polizzi A, Parisi P, and Ruggieri M
- Subjects
- Brain pathology, Electroencephalography, Epilepsy etiology, Humans, Infant, Syndrome, Brain physiopathology, Epilepsy genetics, Mutation
- Abstract
Ohtahara syndrome or Early Infantile Epileptic Encephalopathy (EIEE) with Suppression-Burst, is the most severe and the earliest developing age-related epileptic encephalopathy. Clinically, the syndrome is characterized by early onset tonic spasms associated with a severe and continuous pattern of burst activity. It is a debilitating and early progressive neurological disorder, resulting in intractable seizures and severe mental retardation. Specific mutations in at least four genes (whose protein products are essential in lower brain's neuronal and interneuronal functions, including mitochondrial respiratory chains have been identified in unrelated individuals with EIEE and include: (a) the ARX (aristaless-related) homeobox gene at Xp22.13 (EIEE-1 variant); (b) the CDKL5 (SYK9) gene at Xp22 (EIEE-2 variant); (c) the SLC25A22 (GC1) gene at 11p15.5 (EIEE-3 variant); and (d) the Stxbp1 (MUNC18-1) gene at 9q34-1 (EIEE-4 variant). A yet unresolved issue involves the relationship between early myoclonic encephalopathy (EME-ErbB4 mutations) versus the EIEE spectrum of disorders., (Copyright © 2011 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
14. An 11-year follow-up study of neonatal-onset, bath-induced alternating hemiplegia of childhood in twins.
- Author
-
Incorpora G, Pavone P, Polizzi A, Cocuzza M, Privitera M, Pavone L, and Ruggieri M
- Subjects
- Child, Electroencephalography, Epilepsy diagnosis, Female, Humans, Longitudinal Studies, Twins, Monozygotic, Baths adverse effects, Epilepsy etiology, Hemiplegia complications, Hemiplegia etiology
- Abstract
The authors previously reported on the initial manifestations in a set of female twins, who presented soon after birth with bath-induced paroxysmal events each time they were immersed in a warm water bath. These episodes progressively ceased by the age of 36 months, replaced by paroxysmal episodes of alternating hemiplegia unrelated to water immersion. By age 4 years, the twins developed the classic features of alternating hemiplegia of childhood. Clinical outcomes at the age of 11 years are now reported. Standard and video-electroencephalograms showed a large, slow background activity followed by lower amplitude waves without focal abnormalities or other abnormal findings. This represents the first report on (a) alternating hemiplegia of childhood started with bath-induced paroxysmal episodes; (b) this condition in monozygotic twins; and (c) an 11-year follow-up study in which the twins continue to experience episodes of alternating hemiplegia in the setting of baseline cognitive impairment without epileptic episodes.
- Published
- 2012
- Full Text
- View/download PDF
15. Long-term outcome of epilepsy in Kabuki syndrome.
- Author
-
Verrotti A, Agostinelli S, Cirillo C, D'Egidio C, Mohn A, Boncimino A, Coppola G, Spalice A, Nicita F, Pavone P, Gobbi G, Grosso S, Chiarelli F, and Savasta S
- Subjects
- Abnormalities, Multiple physiopathology, Child, Electroencephalography trends, Epilepsy physiopathology, Face abnormalities, Face physiopathology, Female, Hematologic Diseases physiopathology, Humans, Male, Time Factors, Treatment Outcome, Vestibular Diseases physiopathology, Abnormalities, Multiple diagnosis, Epilepsy complications, Epilepsy diagnosis, Hematologic Diseases complications, Hematologic Diseases diagnosis, Vestibular Diseases complications, Vestibular Diseases diagnosis
- Abstract
Unlabelled: PURPOSES AND METHODS: Kabuki syndrome (KS) is a rare dysmorphic disorder characterized by multiple congenital anomalies and mental retardation. Although epilepsy is one of the most common clinical complications associated with KS, few studies have evaluated its electroclinical aspects and long-term outcome. Therefore, we describe here a clinical series of 10 Caucasian KS patients who developed epilepsy in childhood. We followed all children for at least 5 years., Results: All patients presented partial seizures and interictal EEGs revealed focal epileptic paroxysms with prevalent involvement of temporo-occipital areas. Seven children had no central nervous system abnormalities, but enlargement of lateral ventricles, corpus callosum hypoplasia, and adenohypophysis hypoplasia were revealed in three. Although antiepileptic drug (AED) treatment was effective in controlling seizures and normalizing EEG abnormalities in 8 patients, the other 2 cases were resistant to multiple AEDs. In one of these two patients, withdrawal of AED resulted in status epilepticus and death., Conclusions: Partial seizures and temporo-occipital abnormalities on interictal EEG are common features of KS patients who suffer from epilepsy. Prognosis of this epilepsy is favourable in the majority of cases with complete disappearance of seizures and EEG abnormalities., (Copyright © 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
16. Alternating Hemiplegia of Childhood: neurological comorbidities and intrafamilial variability
- Author
-
Pavone, Piero, Pappalardo, Xena Giada, Mustafa, Naira, Cho, Sung Yoon, Jin, Dong Kyu, Incorpora, Gemma, Falsaperla, Raffaele, Marino, Simona Domenica, Corsello, Giovanni, Parano, Enrico, and Ruggieri, Martino
- Published
- 2022
- Full Text
- View/download PDF
17. Febrile infection-related Epilepsy Syndrome (FIRES): a severe encephalopathy with status epilepticus. Literature review and presentation of two new cases.
- Author
-
Pavone, Piero, Corsello, Giovanni, Raucci, Umberto, Lubrano, Riccardo, Parano, Enrico, Ruggieri, Martino, Greco, Filippo, Marino, Silvia, and Falsaperla, Raffaele
- Subjects
- *
COGNITION disorders , *ONLINE information services , *MEDICAL databases , *STATUS epilepticus , *BRAIN diseases , *MEDICAL information storage & retrieval systems , *FEBRILE seizures , *EPILEPSY , *SYSTEMATIC reviews , *INFECTION , *SEVERITY of illness index , *LITERATURE reviews , *SEIZURES (Medicine) , *MEDLINE - Abstract
FIRES is defined as a disorder that requires a prior febrile infection starting between 2 weeks and 24 h before the onset of the refractory status epilepticus with or without fever at the onset of status epilepticus. The patients, previously normal, present in the acute phase recurrent seizures and status epilepticus followed by a severe course with usually persistent seizures and residual cognitive impairment. Boundary with "new onset refractory status epilepticus (NORSE) has not clearly established. Pathogenetic hypothesis includes inflammatory or autoimmune mechanism with a possible genetic predisposition for an immune response dysfunction. Various types of treatment have been proposed for the treatment of the acute phase of the disorder to block the rapid seizures evolution to status epilepticus and to treat status epilepticus itself. Prognosis is usually severe both for control of the seizures and for cognitive involvement. FIRES is an uncommon but severe disorder which must be carefully considered in the differential diagnosis with other epileptic encephalopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Novel malformations: Chiari type 1 and hydrocephalus in Zhu‐Tokita‐Takenouchi‐Kim syndrome and novel SON variants.
- Author
-
Pavone, Piero, Saia, Federica, Pappalardo, Xena, Barbagallo, Massimo, Prato, Adriana, and Rizzo, Renata
- Subjects
- *
ARNOLD-Chiari deformity , *HYDROCEPHALUS , *SYNDROMES , *GENETIC variation , *DEVELOPMENTAL delay , *EPILEPSY , *INTELLECTUAL disabilities - Abstract
Zhu‐Tokita‐Tachenouchi‐Kim syndrome (ZTTK) is a recently recognized malformation syndrome presenting with craniofacial dysmorphism, developmental delay/intellectual disability, seizures, anomalies involving brain white matter, and other body‐organs. In humans, the disorder is linked to the loss‐of‐function variants in the SON gene (MIM# 617140). Herewith, a new case of this syndrome is reported in a 2‐year‐old Caucasian child who presented the classical clinical features of the ZTTK syndrome in association with hydrocephalus and Chiari malformations type 1 an anomaly previously unreported. Exome analysis showed a de novo heterozygous variant in SON gene. Literature review of similar cases is reported. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Pathogenic correlation between mosaic variegated aneuploidy 1 (MVA1) and a novel BUB1B variant: a reappraisal of a severe syndrome.
- Author
-
Pavone, Piero, Pappalardo, Xena Giada, Mustafa, Naira, Falsaperla, Raffaele, Marino, Simona Domenica, Corsello, Giovanni, Bianca, Sebastiano, Parano, Enrico, and Ruggieri, Martino
- Subjects
- *
ANEUPLOIDY , *FETAL growth retardation , *EPILEPSY , *GROWTH disorders , *SPINDLE apparatus , *OCULAR hypotony - Abstract
Background: The BUB 1 mitotic checkpoint serine/threonine kinase B (BUB1B) gene encodes a key protein in the mitotic spindle checkpoint, which acts as a surveillance mechanism, crucial for the maintenance of the correct chromosome number during cell deviation. Mutations of BUB1B gene are linked to mosaic variegated aneuploidy 1 (MVA1) syndrome, a rare autosomal recessive disorder characterized by widespread mosaic aneuploidies, involving different chromosomes and tissues. MVA1 is clinically characterized by intrauterine growth restriction, post-natal growth retardation, and severe neurologic impairment including microcephaly, developmental delay/intellectual disability, epileptic seizures, and generalized hypotonia. Malignancies are also serious sequelae associated with the disorder. We reported on a case of two-year-old Italian girl with MVA1 who shows severe neurologic impairment, microcephaly and epileptic seizures. Materials and methods: Clinical data collection and genetic diagnosis of the patient were assessed. Mutational analysis covers the chromosomal microarray analysis, the gene methylation pattern studied using the methylation-specific multiplex ligation-dependent probe amplification, and the family-based Whole Exome Sequencing (WES). A literature research based on reported cases of MVA and premature chromatid separation was also included. Results: Karyotyping has revealed 12% of mosaics in the patient who carries a novel variant in BUB1B gene (c.2679A > T, p.Arg893Ser) detected by WES. Thirty-one cases of MVA1 including the present report, and four prenatally diagnosed cases with MVA1 were selected and inspected. Conclusion: Clinical and genetic findings reported in the girl strongly suggest a new MVA1 genotype–phenotype correlation and lead to a reappraisal of a severe syndrome. Diagnosis and in-depth follow-up provided worthwhile data. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Malformations of Cortical Development, Cognitive Involvement and Epilepsy: A Single Institution Experience in 19 Young Patients.
- Author
-
Venti, Valeria, Consentino, Maria Chiara, Smilari, Pierluigi, Greco, Filippo, Oliva, Claudia Francesca, Fiumara, Agata, Falsaperla, Raffaele, Ruggieri, Martino, and Pavone, Piero
- Subjects
EPILEPSY ,CONGENITAL disorders ,CEREBRAL cortex ,COGNITION disorders ,COMORBIDITY - Abstract
Background. Malformations of cortical development (MCD) include a wide range of congenital disorders mostly causing severe cognitive dysfunction and epilepsy. Objective: to report on clinical features including cognitive involvement, epileptic seizures with response to antiseizure medications, comorbidities in young patients affected by MCD and followed in a single tertiary hospital. Patients and methods: A retrospective review of the medical records and magnetic resonance images (MRI) of 19 young patients with an age ranging between eight days and fifteen years affected by MCD and admitted to Pediatrics Department University of Catania, Italy from October 2009 and October 2020 were selected. Patients were distinguished in three groups following the Barcovich et al. 2012 classification for MCD: 4 (21%) in Group I; 8 (42%) in Group II; and, and 7 (37%) in Group III. Clinical features and MRI of the patients including cognitive involvement, epilepsy type and response to drugs treatment were analyzed. Results: In Group I, two patients showed cortical dysplasia and two dysembryoplastic neuroepithelial tumors plus focal cortical dysplasia; developmental delay/intellectual disability (DD/ID) was severe in one, moderate in one and absent in two; the type of seizures was in all the cases focal to bilateral tonic-clonic (FBTCs), and drug resistant was found in one case. In Group II, three patients showed neuronal hetero-topias and five had pachygyria-lissencephaly: DD/ID was severe in four, moderate in two, and absent in two; the type of seizure was focal (FS) in five, focal to bilateral tonic-clonic (FBTCs) in two, infantile spasms (IS) in one, and drug resistant was found in three. In Group III, six showed polymicrogyria and one schizencephaly: DD/ID was found severe in five, moderate in two, and the type of seizure was focal (FS) in five, FBTCS in two, and drug resistance was found in three. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Single and in combination antiepileptic drug therapy in children with epilepsy: how to use it.
- Author
-
Oliva, Claudia Francesca, Gangi, Gloria, Marino, Silvia, Marino, Lidia, Messina, Giulia, Sciuto, Sarah, Cacciaguerra, Giovanni, Comella, Mattia, Falsaperla, Raffaele, and Pavone, Piero
- Subjects
COMBINATION drug therapy ,EPILEPSY ,CHILDHOOD epilepsy ,CHILDREN with epilepsy ,ANTICONVULSANTS ,DRUG dosage - Abstract
Treatment of childhood seizures is a pressing challenge within neuropediatrics because of its severe impact to the children and families affected by these debilitating disorders. It is of upmost importance to make an early diagnosis, to start a promptly treatment, to use therapy and dosage of the drug appropriately, based on the specific epileptic type and epileptic syndrome. Single therapy with appropriate dosage is the main approach to treatment. When the drug is the cause of an idiosyncratic reaction it is advisable to replace the suboptimal seizure response with another antiepileptic drug, combined therapy with two antiepileptic drugs is also a viable option. In childhood, polytherapy using more than two antiepileptic drugs remains controversial because the harm of interaction with deleterious drugs could potentially replace the damage caused by the seizures themselves. The use of three or more antiepileptic drugs should be limited to epileptic seizures that are particularly resistant to drugs and when non-drug antiepileptic therapies have failed. An approach to the difficult topic of epileptic treatment in childhood is reported. Key point: mono vs polytherapy in epileptic children; single and alternative therapy in epileptic children; use or three or more AEDs in children. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. Cerebral Palsy and Epilepsy in Children: Clinical Perspectives on a Common Comorbidity.
- Author
-
Pavone, Piero, Gulizia, Carmela, Le Pira, Alice, Greco, Filippo, Parisi, Pasquale, Di Cara, Giuseppe, Falsaperla, Raffaele, Lubrano, Riccardo, Minardi, Carmelo, Spalice, Alberto, and Ruggieri, Martino
- Subjects
CEREBRAL palsy ,TREATMENT of epilepsy ,AGE groups ,QUADRIPLEGIA ,HEMIPLEGIA - Abstract
Cerebral palsy (CP) is a frequent cause of childhood disability often associated with a complex group of disorders, including epilepsy, which is reported to impact approximately 40% of affected individuals. This retrospective study involved a group of children affected by CP, some of whom also had comorbid epilepsy. The aim of this study was to report our experience of analyzing, in particular, (a) some of the clinical aspects of the different type of CP, and (b) the relationship between the clinical data of children affected by CP plus epilepsy and each type of CP. Methods: This retrospective single-center study was performed with 93 children admitted to the Pediatric Department of the University of Catania, Italy, affected by CP and distinguished according to the type of motor clinical presentation, with 46 showing epileptic seizures, compared to a control group of 136 children affected by epilepsy without other neurologic disorders. Results: Among the 93 CP children, 25 (27%) had spastic quadriplegia (plus one patient with dystonic quadriplegia), 39 (42%) had spastic hemiplegia, 11 (12%) had spastic diplegia (plus two with ataxia and one with dyskinetic CP), and 14 (15%) did not have a well-defined type of CP. The frequency of epilepsy was higher in affected CP children who showed major motor dysfunction (GMFCS IV-V types). As regards the 46 children with CP plus epilepsy, compared to the group of the control, the age of epilepsy onset was found to be statistically significant: 21 ± 35.1 months vs. 67 ± 39.7. Conclusions: Epilepsy represents one of the most frequent comorbidities of cerebral palsy. In children with CP, particular attention should be paid to the early identification and treatment of comorbid epilepsy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Cannabidiol Treatment for Refractory Epilepsies in Pediatrics.
- Author
-
Raucci, Umberto, Pietrafusa, Nicola, Paolino, Maria Chiara, Di Nardo, Giovanni, Villa, Maria Pia, Pavone, Piero, Terrin, Gianluca, Specchio, Nicola, Striano, Pasquale, and Parisi, Pasquale
- Subjects
CANNABIDIOL ,LENNOX-Gastaut syndrome ,CHILDHOOD epilepsy ,NEUROLOGICAL disorders ,EPILEPSY ,ANTICONVULSANTS ,PHENOBARBITAL - Abstract
Cannabis extracts in oil are becoming increasingly available, and, during the last years, there has been growing public and scientific interest about therapeutic properties of these compounds for the treatment of several neurologic diseases, not just epilepsy. The discovered role of the endocannabinoid system in epileptogenesis has provided the basis to investigate the pharmacological use of exogenously produced cannabinoids, to treat epilepsy. Although, physicians show reluctance to recommend Cannabis extracts given the lack of high-quality safety available data, from literature data cannabidiol (CBD) results to be a promising and safe anticonvulsant drug with low side-effect. In particular, according to early studies, CBD can reduce the frequency of seizures and lead to improvements in quality of life in children affected by refractory epilepsy. So, for these reasons, the detailed study of the interactions between CBD and anticonvulsant drugs (AEDs) administered simultaneously in polytherapy, is arousing increasing interest, to clarify and to assess the incidence of adverse effects and the relation between dose escalation and quality of life measures. To date, in pediatric age, CBD efficacy and safety is not supported by well-designed trials and strong scientific evidence are not available. These studies are either retrospective or small-scale observational and only during the last years Class I evidence data for a pure form of CBD have been available, as demonstrated in placebo-controlled RCTs for patients affected by Lennox-Gastaut syndrome and Dravet syndrome. It is necessary to investigate CBD safety, pharmacokinetics and interaction with other AEDs alongside performing double-blinded placebo-controlled trials to obtain conclusive data on its efficacy and safety in the most frequent epilepsies in children, not just in the epileptic encephalopathy. This review was aimed to revise the available data to describe the scientific evidence for CBD in Pediatric Epilepsies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. Molecular Mechanism Involved in the Pathogenesis of Early-Onset Epileptic Encephalopathy.
- Author
-
Vitaliti, Giovanna, Pavone, Piero, Marino, Silvia, Saporito, Marco Andrea Nicola, Corsello, Giovanni, and Falsaperla, Raffaele
- Subjects
EPILEPSY ,ENCEPHALITIS ,DRUG resistance ,CENTRAL nervous system infections ,PATHOLOGICAL physiology - Abstract
Recent studies have shown that neurologic inflammation may both precipitate and sustain seizures, suggesting that inflammation may be involved not only in epileptogenesis but also in determining the drug-resistant profile. Extensive literature data during these last years have identified a number of inflammatory markers involved in these processes of "neuroimmunoinflammation" in epilepsy, with key roles for pro-inflammatory cytokines such as: IL-6, IL-17 and IL-17 Receptor (IL-17R) axis, Tumor-Necrosis-Factor Alpha (TNF-α) and Transforming-Growth-Factor Beta (TGF-β), all responsible for the induction of processes of blood-brain barrier (BBB) disruption and inflammation of the Central Nervous System (CNS) itself. Nevertheless, many of these inflammatory biomarkers have also been implicated in the pathophysiologic process of other neurological diseases. Future studies will be needed to identify the disease-specific biomarkers in order to distinguish epilepsies from other neurological diseases, as well as recognize different epileptic semiology. In this context, biological markers of BBB disruption, as well as those reflecting its integrity, can be useful tools to determine the pathological process of a variety of neurological diseases. However; how these molecules may help in the diagnosis and prognostication of epileptic disorders remains yet to be determined. Herein, authors present an extensive literature review on the involvement of both, systemic and neuronal immune systems, in the early onset of epileptic encephalopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Chromosome 2p15-p16.1 microduplication in a boy with congenital anomalies: Is it a distinctive syndrome?
- Author
-
Pavone, Piero, Falsaperla, Raffaele, Rizzo, Renata, Praticò, Andrea D., and Ruggieri, Martino
- Subjects
- *
HUMAN abnormalities , *CHROMOSOMES , *COMPARATIVE genomic hybridization , *DEVELOPMENTAL delay , *DEVELOPMENTAL neurobiology - Abstract
Abstract Array-based comparative genomic hybridization is a routine technology that helps clinicians in the diagnostic evaluation of individuals presenting with developmental delay or malformation anomalies. With this technique, several patients affected by microdeletion 2p15-p16.1 have been reported and this anomaly has been recognized as a distinct syndrome. In contrast, clinical features of patients with microduplication in the same region have been registered mainly in clinical and genetic data-bases and to date just a single patient has been reported in detail in the literature. A 12-year-old boy with 2p15-p16.1 microduplication presented with moderate neurodevelopment delay, epileptic seizures, behavioral disturbances, and minor dysmorphic features. The role of 2p15-p16.1 duplication in this case, and the others published in data-bases with a similar molecular duplication, are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
26. Electroclinical pattern and epilepsy evolution in an infant with Miller–Dieker syndrome.
- Author
-
Falsaperla, Raffaele, Marino, Simona, Marino, Silvia, and Pavone, Piero
- Subjects
ACADEMIC medical centers ,CHILD development deviations ,SEIZURES (Medicine) ,ELECTROENCEPHALOGRAPHY ,EPILEPSY ,NERVOUS system abnormalities ,SPASMS ,BODY movement - Abstract
Aim of the study: To evaluate the electroclinical course and the correlation Electroencephalographic (EEG) pattern and epileptic seizures in an infant with Miller Dieker Syndrome (MDS) during the first year of life. Materials and Methods: MDS was diagnosed in the infant soon after birth and followed up from six months of life to one year, at the Department of Pediatrics, General Pediatric Operative Unit, Policlinico Vittorio Emanuele, University Hospital, XCatania, Italy, with clinical and serial EEG recording. Results: Aside from severe delay in the developmental milestone, the onset of the seizures was first noticed by the parents at the age of 4 months as brief slow tonic movements; at 6 months as tonic movements of the upper limbs with a slow rotations of the trunk, i.e. “subtle spams”; and at 7 months as typical “infantile spams” and tonic seizures. The EEG recording registered pattern of modified hypsarrhythmia (MH) correlated with “subtle spams” at the age of 6 months and at the age of 7 months the same EEG recording of MH associated to clinical expression of classical Infantile Spams (IS). Conclusions: In this infant, the EEG pattern and epileptic seizures were widely variable ranging clinically from brief anomalous movements to “subtle spams” and to typical infantile spams. At the same time, the EEG recording manifested first with MH and one month later with classical hypsarrhythmia. The EEG recording MH correlated first with clinical expression of subtle spams and the EEG remaining unchanged with the classical clinical expression of infantile spams. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
27. Clinical spectrum of woolly hair: indications for cerebral involvement.
- Author
-
Pavone, Piero, Falsaperla, Raffaele, Barbagallo, Massimo, Polizzi, Agata, Praticò, Andrea D., and Ruggieri, Martino
- Subjects
- *
BRAIN abnormalities , *DISEASE complications , *ENCEPHALITIS , *EPILEPSY , *HAIR , *NEUROLOGICAL disorders , *TREATMENT effectiveness - Abstract
Background: Woolly Hair is an uncommon congenital anomaly of the scalp hair presenting with strongly coiled hair involving a localized area of the scalp or covering the entire side and occurring in non-black people. Isolated or localized wooly hair is usually benign and is not related to other disorders and/or complications. On the contrary, the generalized type may be related to disorders and syndromes affecting heart, cutis, liver and gastrointestinal organs. Among the syndromes presenting with wooly hair, the most known are the Naxos syndrome, the Carvajal- Huerta syndrome, the wooly hair/hypotrichosis, the ectodermal dysplasia-skin fragility, the tricho-hepato-enteric syndrome. Case presentation: To our knowledge, no cases of wooly hair syndromes has been associated to neurologic involvement. Among the clinical notes of patients admitted in the Pediatric Units of the Catania University, we have selected four individuals presenting wooly hair, who showed different clinical features and course: case 1 presenting with a localized wooly hair type; case 2, member of a family affected by WH with autosomal dominant inheritance, not associated to complications; case 3, a wooly hair patient who displayed a progressive, severe form of Rasmussen's encephalitis with fatal evolution, and case 4, wooly hair associated to brain malformation and drug-resistant epilepsy. Conclusions: With this report, we aim to underline the wide spectrum of clinical presentation of individuals with WH and in particular we wish to give an annotation on a possible association of WH with severe neurologic disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. The Gut--brain Axis: A New Pathogenic View of Neurologic Symptoms -- Description of a Pediatric Case.
- Author
-
Falsaperla, Raffaele, Romano, Catia, Pavone, Piero, Vitaliti, Giovanna, Qian Yuan, Motamed-Gorji, Nazgole, and Lubrano, Riccardo
- Subjects
SEIZURES (Medicine) ,SPASM treatment ,BEHAVIOR modification ,BLOOD-brain barrier ,CELLULAR signal transduction ,DIET in disease ,DIET therapy ,EPILEPSY ,GASTROENTERITIS ,GASTROINTESTINAL diseases ,NEUROLOGIC manifestations of general diseases ,MILK allergy ,THERAPEUTICS - Abstract
Recent literature data have given emphasis to the relationship between gastrointestinal (GI) disorders and neurologic diseases, underlying a new pathogenic pathway: The so‑called “gut–brain axis.” Herein, authors report a case of a 10‑month‑old male infant, admitted for drug‑resistant epilepsy, associated with irritable behavior and GI discomfort, secondary to cow’s milk protein allergy. Seizures were described by parents as upward eye movements that were mostly deviated to the right and were associated with slight extension of his neck. They were infrequent at first, but had increased gradually during the course of 3 days (up to 15–20 times/day). No anticonvulsant therapy was effective. Only a cow’s milk protein‑free diet, accidentally started during a gastroenteritis episode, was effective in stopping seizures. Our case underlines the peculiar vulnerability of the blood–brain barrier under 1 year of age, for which children of this age group experience neurologic manifestations during episodes of systemic inflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
29. Prognostic Challenges of SCN1A Genetic Mutations: Report on Two Children with Mild Features.
- Author
-
Praticò, Andrea D., Falsaperla, Raffaele, Ruggieri, Martino, Corsello, Giovanni, and Pavone, Piero
- Subjects
GENETICS of epilepsy ,EPILEPSY ,GENES ,GENETIC counseling ,GENETIC mutation ,RETROSPECTIVE studies ,SEVERITY of illness index ,PROGNOSIS - Abstract
Mutations in the gene encoding the a-1 subunit of the voltage-gated sodium channel (SCN1A) are associated with variable but usually severe clinical course, both for the epileptic seizures and the cognitive impairment. The purpose of the present study was to retrospectively review two patients affected by seizures and two different types of SCN1A gene mutations (microdeletion and point mutation). The children (a 4-year-old girl and a 3-year-old boy) were affected by generalized tonic-clonic seizures and myoclonic jerks plus unilateral seizures, respectively. Genetic analyses showed, in the girl, the presence of a 4 MB deletion involving SCN1A and four other genes, and a point mutation in the boy. Both the patients showed a mild clinical course, with a good pharmacological control of the crises and sufficient scholastic performances. At present, the role of the combination of SCN1A mutations and the related clinical manifestations is not very clear. Prognostic counseling is particularly challenging given that, inmany cases, the clinical course of these patients is independent of the genotype and its severity is difficult to predict. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
30. Clinical dissection of early onset absence epilepsy in children and prognostic implications.
- Author
-
Agostinelli, Sergio, Accorsi, Patrizia, Beccaria, Francesca, Belcastro, Vincenzo, Canevini, Maria Paola, Capovilla, Giuseppe, Cappanera, Silvia, Bernardina, Bernardo Dalla, Darra, Francesca, Gaudio, Luigi Del, Elia, Maurizio, Falsaperla, Raffaele, Giordano, Lucio, Gobbi, Giuseppe, Minetti, Carlo, Nicita, Francesco, Parisi, Pasquale, Pavone, Piero, Pezzella, Marianna, and Sesta, Michela
- Subjects
DISSECTION ,EPILEPSY ,PROGNOSIS ,ANTICONVULSANTS ,THERAPEUTICS ,DISEASE relapse - Abstract
Purpose To investigate whether patients with typical absence seizures ( TAS) starting in the first 3 years of life, conformed to Panayiotopoulos's definition of childhood absence epilepsy ( CAE), show different electroclinical course than those not fulfilling CAE criteria. Methods In this multicenter retrospective study, we choose a fixed duration follow-up of 36 months to examine the electroclinical course of epilepsy in all children with TAS starting before 3 years of age. The probands who fulfilled Panayiotopoulos's criteria for CAE were classified as having pure early onset absence epilepsy (P- EOAE), whereas those who did not as nonpure EOAE ( NP- EOAE). In addition, these two groups of patients were further stratified according to the number of antiepileptic drugs taken to obtain initial seizure control (mono-, bi-, and tritherapy). Key Findings Patients with P- EOAE (n = 111) showed earlier initial seizure control (p = 0.030) and better seizure-free survival curve (p = 0.004) than those with NP- EOAE (n = 77). No mutation in SLC2A1 gene or abnormal neuroimaging was observed in P- EOAE. Among patients with NP- EOAE, those receiving tritherapy showed increased risk of structural brain abnormalities (p = 0.001) or SLC2A1 mutations (p = 0.001) but fewer myoclonic features (p = 0.031) and worse seizure-free survival curve (p = 0.047) than those treated with mono- and bitherapy. Children with NP- EOAE had 2.134 the odds of having relapse during the follow-up compare to those with P- EOAE. Significance Children with early onset TAS who did meet Panayiotopoulos's criteria showed a favorable course of epilepsy, whereas patients not fulfilling Panayiotopoulos's criteria showed increased risk of relapse at long-term follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
31. Psychogenic Non-Epileptic Seizures: A Diagnostic Problem Difficult to Solve in Clinical Practice.
- Author
-
VERROTTI, Alberto, PAVONE, Piero, AGOSTINELLI, Sergio, NANNI, Giuliana, and GOBBI, Giuseppe
- Subjects
- *
SEIZURES diagnosis , *SEIZURES (Medicine) , *DIFFERENTIAL diagnosis , *EPILEPSY , *SPASMS , *PSYCHOSOMATIC disorders , *DIAGNOSIS - Abstract
Psychogenic non-epileptic seizures (PNES) are defined as episodes of altered movements, sensations, and behaviours that resemble epileptic seizures but that are not associated with abnormal electrical brain discharges. The incidence of PNES in the general population is relatively low (about 1.5/100.000 persons per year), but the data from epilepsy centres show a much higher incidence rate. The identification of this pathological entity has significantly increased in the last years, also thanks to the setting-up of video-electroencephalography. The main challenge for physicians and neurologists is to distinguish PNES from epileptic seizures. The aim of this review was to analyse the clinical aspects and the diagnostic problems of PNES in epileptic patients in order to give practical advices for the identification of this problem and for distinguishing PNES from epileptic seizures. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
32. Infantile spasms in the setting of Sturge–Weber syndrome.
- Author
-
Barbagallo, Massimo, Ruggieri, Martino, Incorpora, Gemma, Pavone, Piero, Nucifora, Caterina, Spalice, Alberto, Praticò, Andrea Domenico, Polizzi, Agata, Pavone, Lorenzo, and Iannetti, Paola
- Subjects
SEIZURES (Medicine) ,SPASMS ,ELECTROENCEPHALOGRAPHY ,EPILEPSY ,NEUROLOGICAL disorders ,BRAIN diseases - Abstract
The prevalence and outcome of the most frequent type of epilepsy in infancy–infantile spasms (IS)—are well characterized in the setting of most neurocutaneous disorders. By contrast, still there is no study describing the natural history of IS in the setting of Sturge–Weber syndrome (SWS). Two patients with SWS and IS were identified in our series and five in the literature. The aim of study is to evaluate the clinical, electroencephalographic (EEG) and imaging features of our cases and to compare our cases with those described in the literature. IS in the setting of SWS is an uncommon but possible event (2/19 patients seen over 13 years in our institutions). We confirmed the correlation between IS and severity of SWS cutaneous and neural (extension of leptomeningeal capillary malformation) phenotype. IS in SWS seems to be atypical both from a clinical viewpoint (they are asymmetric) and from a laboratory viewpoint (EEG is not classically hypsarrhythmic). [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
33. Clinical heterogeneity in eyelid myoclonia, with absences, and epilepsy.
- Author
-
Incorpora, Gemma, Sofia, Vito, Pavone, Piero, Biondi, Roberto, Barone, Baldo, and Parano, Enrico
- Subjects
SPASMS ,MYOCLONUS ,VALPROIC acid ,EYE diseases ,EPILEPSY - Abstract
Eyelid myoclonia with absences should always be considered in the investigation of children with epilepsy. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
34. Benign and severe early-life seizures: a round in the first year of life.
- Author
-
Pavone, Piero, Corsello, Giovanni, Ruggieri, Martino, Marino, Silvia, Marino, Simona, and Falsaperla, Raffaele
- Subjects
- *
SEIZURES diagnosis , *GENETICS of epilepsy , *SPASM treatment , *BRAIN diseases , *AGE factors in disease , *CHILD development deviations , *DRUG resistance , *EPILEPSY , *SEIZURES (Medicine) , *FEBRILE seizures , *INFANT development , *PEOPLE with intellectual disabilities , *INFANTILE spasms , *SEVERITY of illness index , *SPASMS , *OPSOCLONUS-Myoclonus syndrome , *SYMPTOMS , *CHILDREN , *PROGNOSIS , *DIAGNOSIS , *THERAPEUTICS - Abstract
Background: At the onset, differentiation between abnormal non-epileptic movements, and epileptic seizures presenting in early life is difficult as is clinical diagnosis and prognostic evaluation of the various seizure disorders presenting at this age. Seizures starting in the first year of life including the neonatal period might have a favorable course, such as in infants presenting with benign familial neonatal epilepsy, febrile seizures simplex or acute symptomatic seizures. However, in some cases, the onset of seizures at birth or in the first months of life have a dramatic evolution with severe cerebral impairment. Seizure disorders starting in early life include the "epileptic encephalopathies", a group of conditions characterized by drug resistant seizures, delayed developmental skills, and intellective disability. This group of disorders includes early infantile epileptic encephalopathy also known as Ohtahara syndrome, early myoclonic encephalopathy, epilepsy of infancy with migrating focal seizures, infantile spasms syndrome (also known as West syndrome), severe myoclonic epilepsy in infancy (also known as Dravet syndrome) and, myoclonic encephalopathies in non-progressive disorder. Here we report on seizures manifesting in the first year of life including the neonatal period. Conditions with a benign course, and those with severe evolution are presented. At this early age, clinical identification of seizures, distinction of each of these disorders, type of treatment and prognosis is particularly challenging. The aim of this report is to present the clinical manifestations of each of these disorders and provide an updated review of the conditions associated with seizures in the first year of life. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
35. Temporal Triangular Alopecia in Association With Mental Retardation and Epilepsy in a Mother and Daughter.
- Author
-
Ruggieri, Martino, Rizzo, Renata, Pavone, Piero, Baieli, Sabrina, Sorge, Giovanni, and Happle, Rudolph
- Subjects
BALDNESS ,INTELLECTUAL disabilities ,EPILEPSY ,DISEASE complications ,MOTHER-daughter relationship - Abstract
Presents correspondence examining the influence of temporal triangular alopecia (TTA) in association with mental retardation and epilepsy in a mother and daughter. Disease characteristics; Clinical features; Frequency of epilepsy and mental retardation and TTA.
- Published
- 2000
- Full Text
- View/download PDF
36. Clinical and electroencephalographic features of epilepsy in patients with triple X syndrome. A case series
- Author
-
Giovanni Battista Dell'Isola, Elisabetta Mencaroni, Paolo Prontera, Giuseppe Di Cara, Luigi Ferraro, Paolo Bonanni, Marco Carotenuto, Giulia Iapadre, Sara Matricardi, Francesca Operto, Alessandro Orsini, Pasquale Parisi, Piero Pavone, Vincenzo Salpietro, Salvatore Savasta, Pasquale Striano, Alberto Verrotti, Dell'Isola, Giovanni Battista, Mencaroni, Elisabetta, Prontera, Paolo, Cara, Giuseppe Di, Ferraro, Luigi, Bonanni, Paolo, Carotenuto, Marco, Iapadre, Giulia, Matricardi, Sara, Operto, Francesca, Orsini, Alessandro, Parisi, Pasquale, Pavone, Piero, Salpietro, Vincenzo, Savasta, Salvatore, Striano, Pasquale, and Verrotti, Alberto
- Subjects
focal epilepsy ,levetiracetam (lev) ,Levetiracetam ,Epilepsy ,triple x syndrome ,Valproic Acid ,anti-seizure medication (asm) ,Electroencephalography ,General Medicine ,valproic acid (vpa) ,Neurology ,Humans ,Female ,Anticonvulsants ,Neurology (clinical) ,Retrospective Studies - Abstract
Purpose: Triple X syndrome, is an often undiagnosed chromosomal abnormality with an incidence of 1/1000 females. Main associated disorders are urogenital malformations, premature ovarian failure or primary amen-orrhea, gastrointestinal problems, psychiatric disorders and epilepsy. To date, triple X is not related to a specific epileptic syndrome. Therefore, the purpose of this clinical series is to analyze seizure semiology, electroen-cephalogram features and the long-term outcome of 13 patients with epilepsy and triple X syndrome.Methods: We retrospectively evaluated the long-term seizure outcome in patients with triple X syndrome who had been referred to 11 Epilepsy Centers in Italy. A close electroclinical follow-up was made for at least 2 years and outcomes were reported.Results: Our case series confirms that epilepsy is not an occasional finding but part of the phenotypic spectrum of this syndrome. The seizure semiology shows an higher prevalence of focal seizures in 62% of patients. EEG findings of focal epileptic activity were reported in 85% of patients. Anti-seizure medications were successful in all our patients whom in most cases were responsive to monotherapy.Conclusion: According to our case series most successful drugs were VPA and LEV. Long term prognosis of epi-lepsy in our case series was good. Our experience suggests that all triple X patients achieve good seizure control and in 69% of cases normalization of the EEG.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.